Metabolomics

Dataset Information

0

Leptin increases hepatic triglyceride export via a vagal mechanism in humans


ABSTRACT: Recombinant human leptin (metreleptin) reduces hepatic lipid content in patients with lipodystrophy and overweight patients with non-alcoholic fatty liver disease and relative hypoleptinemia independent of its anorexic action. In rodents, leptin signaling in the brain increases very-low-density lipoprotein triglyceride (VLDL-TG) secretion and reduces hepatic lipid content via the vagus nerve. In this randomized, placebo-controlled crossover trial (EudraCT Nr. 2017-003014-22), we tested whether a comparable mechanism regulates hepatic lipid metabolism in humans. A single metreleptin injection stimulated hepatic VLDL-TG secretion (primary outcome) and reduced hepatic lipid content in fasted, lean men (n = 13, age range 20-38 years) but failed to do so in metabolically healthy liver transplant recipients (n = 9, age range 26-62 years) who represent a model for hepatic denervation. In an independent cohort of lean men (n = 10, age range 23-31 years), vagal stimulation by modified sham feeding replicated the effects of metreleptin on VLDL-TG secretion. Therefore, we propose that leptin has anti-steatotic properties that are independent of food intake by stimulating hepatic VLDL-TG export via a brain-vagus-liver axis.

INSTRUMENT(S): Liquid Chromatography MS - alternating - reverse phase

SUBMITTER: Nara Marella 

PROVIDER: MTBLS4231 | MetaboLights | 2023-06-07

REPOSITORIES: MetaboLights

Dataset's files

Source:
Action DRS
MTBLS4231 Other
FILES Other
a_MTBLS4231_LC-MS_alternating_reverse-phase_metabolite_profiling.txt Txt
files-all.json Other
i_Investigation.txt Txt
Items per page:
1 - 5 of 7
altmetric image

Publications


Recombinant human leptin (metreleptin) reduces hepatic lipid content in patients with lipodystrophy and overweight patients with non-alcoholic fatty liver disease and relative hypoleptinemia independent of its anorexic action. In rodents, leptin signaling in the brain increases very-low-density lipoprotein triglyceride (VLDL-TG) secretion and reduces hepatic lipid content via the vagus nerve. In this randomized, placebo-controlled crossover trial (EudraCT Nr. 2017-003014-22), we tested whether a  ...[more]

Similar Datasets

2022-06-29 | GSE203290 | GEO
2013-09-15 | E-GEOD-32515 | biostudies-arrayexpress
2013-09-15 | GSE32515 | GEO
2010-05-18 | E-GEOD-13936 | biostudies-arrayexpress
2009-12-10 | GSE13936 | GEO
2021-03-15 | GSE134777 | GEO
2010-05-27 | E-GEOD-21211 | biostudies-arrayexpress
2021-03-15 | PXD021826 | Pride
2010-05-27 | GSE21211 | GEO
2024-02-12 | GSE253701 | GEO